Gross margin
7.3% Fiscal year 2025
Rank 4 of 100: higher than 4% of 370 peers (All). weak.
Rank 7 of 100: higher than 7% of 49 peers (Sector). weak.
Median Health Care: 61.8%
Share of revenue left after the direct cost of the products sold.
Health Care · Fundamental analysis
Metrics from daily candles, as of Nov 20, 2026 · Extended universe
Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year
Centene is a health insurer from St. Louis that specializes in government-funded programs. It covers many members in the Medicaid program for people with low incomes, in marketplace plans under the “Obamacare” law and in Medicare. As of Oct 11, 2026
According to the company, Centene is a managed care company focused on underserved populations and is incorporated in Delaware. In 2025 Centene operated in the segments Medicaid, Medicare, commercial insurance and other. The Medicaid segment includes programs for low-income families with children, for elderly, blind or disabled people and for long-term care, among others. The Medicare segment includes Medicare Advantage, special plans for people eligible for both programs, stand-alone prescription drug plans and supplemental insurance. The commercial segment offers policies through the Health Insurance Marketplace as well as individual and group insurance. Centene offers Medicare Advantage mainly under the Wellcare brand.
Automatically summarized from SEC annual report (10-K, filed Feb 17, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 15, 2026
Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis
Centene Corporation · Sector Health Care · amounts in USD
Source: SEC filings, As of Feb 17, 2026.
For you first Dividend
The company pays no dividend.
Dividend at a glance Dividends and buybacks per year “Dividend” check What matters for dividend investors
For you first Valuation
There is no comparison for the P/E: the last fiscal year ended with a loss.
With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free
Valuation against its own history Valuation over time Comparison with the sector What matters for value investors
For you first Growth
How strongly revenue and earnings per share have grown over the years.
“Growth” check Figures over time Consistency What matters for growth investors
For you first Quality
How much of revenue remains and whether profit arrives as cash.
“Quality” check Earnings quality What matters for quality investors
For you first Trading
The overview of this stock shows the trend by timeframe.
To the overview Chart patterns of this stock What matters for traders
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
Fiscal year to Dec 31, 2025
7.3% Fiscal year 2025
Rank 4 of 100: higher than 4% of 370 peers (All). weak.
Rank 7 of 100: higher than 7% of 49 peers (Sector). weak.
Median Health Care: 61.8%
Share of revenue left after the direct cost of the products sold.
−3.9% Fiscal year 2025
Rank 12 of 100: higher than 12% of 470 peers (All). weak.
Rank 8 of 100: higher than 8% of 54 peers (Sector). weak.
Median Health Care: 17.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
−3.4% Fiscal year 2025
Rank 11 of 100: higher than 11% of 584 peers (All). weak.
Rank 10 of 100: higher than 10% of 63 peers (Sector). weak.
Median Health Care: 12.9%
Profit after all costs, interest and taxes divided by revenue.
−33.4% Fiscal year 2025
Rank 5 of 100: higher than 5% of 544 peers (All). weak.
Rank 3 of 100: higher than 3% of 54 peers (Sector). weak.
Median Health Care: 12.8%
Net income divided by equity at fiscal year end.
−8.7% Fiscal year 2025 (total assets at year end)
Rank 6 of 100: higher than 6% of 594 peers (All). weak.
Rank 7 of 100: higher than 7% of 63 peers (Sector). weak.
Median Health Care: 6.6%
Net income divided by total assets at fiscal year end.
26.0% Fiscal year 2025
Rank 33 of 100: higher than 33% of 595 peers (All). medium.
Rank 23 of 100: higher than 23% of 63 peers (Sector). weak.
Median Health Care: 44.2%
Equity as a share of total assets. Usually low for banks.
2.2% Fiscal year 2025
Rank 21 of 100: higher than 21% of 465 peers (All). weak.
Rank 19 of 100: higher than 19% of 61 peers (Sector). weak.
Median Health Care: 14.5%
Free cash flow divided by revenue.
4.3B USD Fiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
+10.5% per year
Rank 69 of 100: higher than 69% of 578 peers (All). strong.
Rank 77 of 100: higher than 77% of 62 peers (Sector). strong.
Median Health Care: +5.1%
Average growth per year over 3 fiscal years.
+11.9% per year
Rank 64 of 100: higher than 64% of 549 peers (All). medium.
Rank 78 of 100: higher than 78% of 60 peers (Sector). strong.
Median Health Care: +7.8%
Average growth per year over 5 fiscal years.
+23.9% per year
Rank 93 of 100: higher than 93% of 412 peers (All). strong.
Rank 89 of 100: higher than 89% of 50 peers (Sector). strong.
Median Health Care: +9.3%
Average growth per year over 10 fiscal years.
4 of 9 Fiscal year 2025
Rank 8 of 100: higher than 8% of 310 peers (All). weak.
Rank 5 of 100: higher than 5% of 47 peers (Sector). weak.
Median Health Care: 6.0 of 9
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
0.88 at fiscal year end
Rank 37 of 100: lower than 37% of 486 peers (All). medium.
Rank 23 of 100: lower than 23% of 50 peers (Sector). weak.
Median Health Care: 0.66
Long-term financial debt divided by equity.
1.10 at fiscal year end
Rank 35 of 100: higher than 35% of 513 peers (All). medium.
Rank 20 of 100: higher than 20% of 63 peers (Sector). weak.
Median Health Care: 1.58
Current assets divided by current liabilities.
−14.9% in 5 years
Rank 85 of 100: lower than 85% of 507 peers (All). strong.
Rank 86 of 100: lower than 86% of 59 peers (Sector). strong.
Median Health Care: −4.3%
Change in diluted share count. Negative = share buybacks, positive = new shares.
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 194.8B USD · Net income −6.7B USD · Net margin −3.4%
How has it gone since the last annual report?
Revenue in the quarter to Sep 2026 +1.9% vs. the same quarter a year earlier; grown for at least 16 quarters in a row.
| Quarter | Revenue | vs. year ago | Net income | Margin |
|---|---|---|---|---|
| Jul–Sep 26 | 50.6B | +1.9% | −71.0M | −0.1% |
| Apr–Jun 26 | 53.6B | +9.9% | 1.1B | 2.0% |
| Jan–Mar 26 | 49.9B | +7.1% | 1.5B | 3.1% |
| Oct–Dec 25* | 49.7B | +21.9% | −1.1B | −2.2% |
| Jul–Sep 25 | 49.7B | +18.2% | −6.6B | −13.3% |
| Apr–Jun 25 | 48.7B | +22.4% | −253.0M | −0.5% |
| Jan–Mar 25 | 46.6B | +15.4% | 1.3B | 2.8% |
| Oct–Dec 24* | 40.8B | +3.4% | 283.0M | 0.7% |
Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.
Each quarter is compared with the same quarter a year earlier.
* derived: fiscal year minus the first 9 months.
As of: 12 months to Sep 30, 2026, filed on Oct 27, 2026 · Source: SEC filings (10-Q, 10-K)
Does the profit arrive as cash?
There was no profit in fiscal year 2025; operating income does not cover interest.
| FY | Cash flow ÷ profit | Interest coverage | Tax rate |
|---|---|---|---|
| 2025 | – | negative | – |
| 2024 | – | 4.5x | 22.6% |
| 2023 | 2.98x | 4.0x | 25.0% |
| 2022 | 5.21x | 2.0x | 38.7% |
| 2021 | 3.15x | 2.7x | 26.3% |
How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.
Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.
As of fiscal year 2025 · Source: SEC filings
How even were the last years?
In 10 fiscal years one loss year and no year with lower revenue.
| FY | Revenue vs. prior year | Net margin |
|---|---|---|
| 2025 | +19.4% | −3.4% |
| 2024 | +5.9% | 2.0% |
| 2023 | +6.5% | 1.8% |
| 2022 | +14.7% | 0.8% |
| 2021 | +13.4% | 1.1% |
| 2020 | +48.9% | 1.6% |
| 2019 | +24.2% | 1.8% |
| 2018 | +24.3% | 1.5% |
| 2017 | +19.1% | 1.7% |
| 2016 | +78.4% | 1.4% |
Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.
As of fiscal years 2016–2025 · Source: SEC filings
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Of 100 USD of revenue, 7.3 USD gross profit remained.
Operating loss: −3.9% of revenue
| Item | Amount | of revenue |
|---|---|---|
| Revenue | 194.8B USD | 100.0% |
| Gross profit | 14.2B USD | 7.3% |
| Cost of revenue | 180.6B USD | 92.7% |
| Operating expenses | 21.8B USD | 11.2% |
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
The operating margin fell in 5 years from 2.8% to −3.9%.
Gross marginOperating marginNet marginReturn on equity fell in 5 years from 7.0% to −33.4%.
Return on equityReturn on assetsThe equity ratio fell in 5 years from 37.5% to 26.0%.
EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.The current ratio stayed roughly the same in 5 years (1.10).
Current ratioFree cash flow fell in 5 years from 4.6B USD to 4.3B USD.
Operating cash flowCapital expenditureFree cash flow in USDThe share count fell in 5 years by 14.9% (mostly through share repurchases).
Diluted share countFrom annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.
No annual figures for this stock: Dividend per share, Payout ratio (earnings), Payout ratio (free cash flow).
Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.
How reliable is the dividend?
The company pays no dividend.
As of fiscal year 2025 · Source: SEC filings
Valued higher or lower than usual?
There is no comparison for the P/E: the last fiscal year ended with a loss.
With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free
Source: SEC filings and our daily candles
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
Over 5 years, 8.6B USD went back to shareholders, 100% of it through share repurchases. This was offset by new shares issued for 232.0M USD (including employee plans).
Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USDDividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users. Log in
Centene Corporation next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
| Symbol | Revenue (FY) | Growth 5 yrs | Gross margin | Op. margin | Net margin | ROE | Equity ratio | FCF margin | Piotroski |
|---|---|---|---|---|---|---|---|---|---|
| UNH UnitedHealth Group | 447.6B USD | +11.7% | – | 4.2% | 2.7% | 12.0% | 32.3% | 3.6% | 7/9 |
| MCK McKesson Corporation | 403.4B USD | +11.1% | 3.6% | 1.5% | 1.2% | – | −2.6% | 1.4% | 6/9 |
| CVS CVS Health | 402.1B USD | +8.4% | – | 1.2% | 0.4% | 2.4% | 29.7% | 1.9% | 7/9 |
| CI Cigna | 274.9B USD | +11.4% | – | 3.3% | 2.2% | 14.3% | 26.4% | – | 7/9 |
| ELV Elevance Health | 199.1B USD | +10.3% | – | 3.6% | 2.8% | 12.9% | 36.1% | 1.6% | 7/9 |
| CNC Centene Corporation this stock | 194.8B USD | +11.9% | 7.3% | −3.9% | −3.4% | −33.4% | 26.0% | 2.2% | 4/9 |
| JNJ Johnson & Johnson | 94.2B USD | +2.7% | 67.9% | – | 28.5% | 32.9% | 40.9% | 20.9% | 4/9 |
| HCA HCA Healthcare | 75.6B USD | +8.0% | – | – | 9.0% | – | −9.9% | 10.2% | – |
| LLY Lilly (Eli) | 65.2B USD | +21.6% | 83.0% | – | 31.7% | 77.8% | 23.6% | 13.8% | 7/9 |
| Median of the sector 27 symbols | 44.6B USD | +9.4% | 67.2% | 17.8% | 13.2% | 13.6% | 38.4% | 14.7% | 7/9 |
Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).
Compare with the closest peer in the sector CNC next to ELV – quality checks, metrics and depth side by side.
Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
+11.9% per year, last 5 years
Sector Health Care: median +8.5% (25 symbols)
What does this mean? Revenue: over 5 years it grew by 11.9% per year on average – at least as fast as the median company in the sector (+8.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
– per year, last 5 years
Sector Health Care: median +5.5% (20 symbols)
per share: not computable (loss in the first or last year)
What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
−3.4% last fiscal year
Sector Health Care: median 13.9% (26 symbols)
What does this mean? Of every 100 USD in revenue there was no profit but a loss of 3.43 USD. Five years ago the margin was 1.6%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
0.70 latest balance sheet
Sector Health Care: median 0.66 (19 symbols)
What does this mean? For every 1 USD of equity there is 0.70 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
– Dividend / earnings per share
Sector Health Care: median 56% (16 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
9 of 10 fiscal years with a profit
What does this mean? In 9 of the last 10 fiscal years the bottom line showed a profit. One year ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 31, 2025 | 194.8B | −6.7B | −3.4% | −13.53 | – | – |
| 2024 | Dec 31, 2024 | 163.1B | 3.3B | 2.0% | 6.31 | – | – |
| 2023 | Dec 31, 2023 | 154.0B | 2.7B | 1.8% | 4.95 | – | – |
| 2022 | Dec 31, 2022 | 144.5B | 1.2B | 0.8% | 2.07 | – | – |
| 2021 | Dec 31, 2021 | 126.0B | 1.3B | 1.1% | 2.28 | – | – |
| 2020 | Dec 31, 2020 | 111.1B | 1.8B | 1.6% | 3.12 | – | – |
| 2019 | Dec 31, 2019 | 74.6B | 1.3B | 1.8% | 3.14 | – | – |
| 2018 | Dec 31, 2018 | 60.1B | 900.0M | 1.5% | 2.26 | – | – |
| 2017 | Dec 31, 2017 | 48.4B | 828.0M | 1.7% | 2.35 | – | – |
| 2016 | Dec 31, 2016 | 40.6B | 562.0M | 1.4% | 1.72 | – | – |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q3/26 | Sep 30, 2026 | 50.6B | −71.0M | −0.1% | −0.14 | – | – |
| Q2/26 | Jun 30, 2026 | 53.6B | 1.1B | 2.0% | 2.19 | – | – |
| Q1/26 | Mar 31, 2026 | 49.9B | 1.5B | 3.1% | 3.11 | – | – |
| Q4/25* | Dec 31, 2025 | 49.7B | −1.1B | −2.2% | – | – | – |
| Q3/25 | Sep 30, 2025 | 49.7B | −6.6B | −13.3% | −13.50 | – | – |
| Q2/25 | Jun 30, 2025 | 48.7B | −253.0M | −0.5% | −0.51 | – | – |
| Q1/25 | Mar 31, 2025 | 46.6B | 1.3B | 2.8% | 2.63 | – | – |
| Q4/24* | Dec 31, 2024 | 40.8B | 283.0M | 0.7% | – | – | – |
| Q3/24 | Sep 30, 2024 | 42.0B | 713.0M | 1.7% | 1.36 | – | – |
| Q2/24 | Jun 30, 2024 | 39.8B | 1.1B | 2.9% | 2.16 | – | – |
| Q1/24 | Mar 31, 2024 | 40.4B | 1.2B | 2.9% | 2.16 | – | – |
| Q4/23* | Dec 31, 2023 | 39.5B | 45.0M | 0.1% | – | – | – |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Per-share values adjusted for stock split Stock splitA company divides each share into several new ones; the value of the company stays the same. We convert per-share values from before the split to today’s scale.Example: Split 4 : 1, earnings per share before $11.89 → comparable today $2.97.More in the Academy: Lesson revenue, profit and margin 2:1 (between Oct 23, 2018 and Feb 19, 2019). Quarters are labeled by the calendar quarter in which they end.
Information only – does not affect the other analysis methods, not investment advice.
| Period | Purchases | Sales | Net |
|---|---|---|---|
| 3 months | $00 people | $3.8M1 person | −$3.8M |
| 6 months | $00 people | $12.1M2 people | −$12.1M |
| 12 months | $00 people | $14.6M2 people | −$14.6M |
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
4 of 26 tracked superinvestors report a position.
| Investor | Weight in portfolio | vs. previous quarter | As of |
|---|---|---|---|
| David Einhorn Greenlight Capital | 2.9% | unchanged | Q3 2026 |
| Bridgewater Associates | 0.4% | +236.2% increased | Q3 2026 |
| Renaissance Technologies | 0.3% | +79.1% increased | Q3 2026 |
| Steve Cohen Point72 Asset Management | 0.2% | +112.6% increased | Q3 2026 |
Sold out in the latest quarter: Paul Tudor Jones.
Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.
We do not calculate a trend score for symbols in the extended universe.
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.
No posts on CNC yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules